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The thesis entitled “Enantioselective Synthesis of (–)-8,4ʹ-Oxyneolignans & Synthesis 
and Bioevaluation of Nitrogen Containing Heterocyclic Compounds” has been divided 
into two parts, Part A and Part B, and each part is further divided into chapters. Each 
chapter except chapter-I (Introduction), is further sub-divided into the following sections: 
Introduction, Present work, Results and discussion, Experimental section, Conclusions, 
References and Spectroscopic data. 
PART A: Deals with the Enantioselective Synthesis of (–)-8,4ʹ-Oxyneolignans, and is 
divided into Chapter I and Chapter II.  
 
Chapter I: Introduction 
This chapter deals with the introduction of important plant metabolites viz., 
lignans, neolignans and 8,4ʹ-oxyneolignans and summarizes some of the reported 
approaches towards the (–)-8,4ʹ-oxyneolignans. This chapter also deals with the 
introduction of the glycolate Evans aldol reaction and our current approach of its 
application in the enantioselective synthesis of (–)-8,4ʹ-oxyneolignans.  
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Figure 1: Srtuctures of ()-virolin (1), ()-surinamensin (2), ()-raphidecursinol B (3) and ()-polysphorin (4).
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Chapter-II: Enantioselective Synthesis of (–)-8, 4ʹ-Oxyneolignans 
 This chapter details our efforts in the enantioselective synthesis                             
of four biologically active 8,4ʹ-oxyneolignans., (–)-Virolin, (–)-Surinamensin,                             
(–)-Raphidecursinol B and (–)-Polysphorin. 
(–)-Virolin, (–)-surinamensin, (–)-raphidecursinol B and (–)-polysphorin are 
optically active 8,4ʹ-oxyneolignans, found in various medicinally important natural 
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products. These compounds, isolated from Myristicaceae and other primitive plant 
families in neotropical regions, belong to one of the major class of neolignans containing 
a chiral aryloxy C(8)-O-C(4ʹ) ether linkage. Virolin (1) and surinamensin (2), isolated 
from the leaves of Virola surinamensis (Myristicaceae), show activity against 
leishmaniasis, fungal and other vector-brone diseases. Raphidecursinol B (3) isolated 
from the seeds (nut meg) of Myristica Fragrans Houtt (Myristicaceae) exhibit activity 
against plasmodium falciparum. Polysphorin (4) isolated from piper polysphorum C in 
China and also from Rhaphidopora decursiva in Vietnam, display anti-malarial activity. 
The four biologically active 8,4ʹ-Oxyneolignans - (–)-virolin (1), (–)-surinamensin (2),   
(–)-raphidecursinol B (3) and (–)-polysphorin (4) - were synthesized using glycolate 
Evans syn-aldol reaction as key step. 
 Scheme 1: Retro-synthetic strategy and the building blocks
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Our strategy is depicted retrosynthetically in Scheme 1. It was envisaged that the 
reductive deoxygenation of the primary hydroxyl group of the diol (II) resulting from the 
auxiliary assisted aldol reaction of suitable substrates would afford the 1-aryl-2-
aryloxypropanol (I) moiety in the required stereochemistry. The auxiliary linked chiral 
precursor (III) could easily be generated from aryloxyacetic acid (V), which in turn could 
be readily prepared from commercially available starting materials (VI).  
The aryloxyacetic acid derivative (7), A-ring precursor for virolin and 
surinamensin was assembled starting from vanillin (5). The aryloxyacetic acid derivative 
(10), A-ring building block of raphidecursinol B and polysphorin was generated starting 
from 2,6-dimethoxyphenol (8) (Scheme 2).  
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Scheme 2: Preparation of aryloxy acetic acid derivatives 7 & 10
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With both A- and B-ring counterparts at our disposal, we proceeded to the crucial 
auxiliary assisted aldol reaction. Reaction of lithium salt of the auxiliary (11) with 
aryloxyacetic acid chlorides 12 and 13 (prepared from 7 & 10) afforded the 
corresponding N-acyl-imidazolidinone derivatives 14 and 15 (Scheme 3). 
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Scheme 3: Synthesis of ()-Virolin (1), ()-Surinamensin (2), ()-Raphidecursinol B (3)
 
The aldol reaction of the boron enolates, generated from imidazolinones 14 and 
15 by treating with di-n-butyl boron triflate in presence of Hünig’s base (i-Pr2NEt) with 
aldehyde afforded only a single diastereomer (>99% from 
1
H-NMR of the crude 
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product). The reductive removal of the auxiliary from the adducts (18, 19 & 20) gave the 
corresponding diols (21, 22 & 23). Deoxygenation of primary hydroxyl group from the 
diols by the tosylation followed by the reductive removal of the tosylate moiety afforded 
(–)-virolin (1), (–)-surinamensin (2) and (–)-raphidecursinol B (3) (Scheme 3). 
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Scheme 4: Preparation of ()-polysphorin (4)  
Finally, the synthesis of (–)-polysphorin (4) was achieved by the isomerization of 
the double bond in (–)-raphidecursinol B (3) (Scheme 4). The spectral characteristics of 
the natural products prepared compare favorably with the literature reported spectral data. 
Structural integrity of 1, 2, 3 and 4 was further confirmed by the specific rotation 
analysis, which matched well with literature reported values. Employing this protocol, the 
overall yields achieved for the final compounds (–)-virolin (1), (–)-surinamensin (2), (–)-
raphidecursinol B (3) and (–)-polysphorin (4) are 70%, 75%, 67% and 65% respectively 
starting from 5 and 8. 
Thus our study resulted in efficient and concise asymmetric total synthesis of 
biologically important plant metabolites (–)-virolin, (–)-surinamensin, (–)-raphidecursinol 
B and (–)-polysphorin has been described using two common intermediates, beginning 
from readily available starting materials. Since these compounds exhibit useful biological 
properties, present strategy facilitates the synthesis of non-natural congeners of the 
natural compounds with better biological profiles. 
 
Part-B: Deals with the synthesis of various heterocyclic compounds and their 
biological evaluation, and is divided into Chapter-III and Chapter-IV. 
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Chapter-III: Synthesis and Selective Cytotoxic Activity of Novel Hybrid Chalcones 
against Prostate Cancer (PC-3) Cells 
This chapter deals with the introduction to natural and synthetic bioactive 
chalcones and their reported structural modifications for the development of new drug 
candidates. It also describes our design strategy, synthetic execution and biological 
evaluation of new hybrid chalcones.  
Design and synthesis of new types of pharmacologically interesting hybrid 
chalcone analogs for drug discovery have gained much attention during recent years. 
Several structural modifications to the chalcone template, particularly replacement of 
either A or B-phenyl ring or both with heterocyclic groups have been shown to enhance 
their biological profiles. Even though dihydrofuro- and pyrano-chalcones are also 
available in nature along with their prenyl- counterparts with good biological properties, 
less attention was drawn towards these classes of compounds. In nature, the dihydrofuro 
and -pyrano fused chalcones are believed to be formed by oxidative cyclization of the 
prenyl analogs. The nature prefers six membered pyrano fused structures to five 
membered furo- fused ones as exemplified by the relatively high abundance of natural 
pyrano- fused chalcones. The less abundant furo fused chalcone derivatives have been 
reported to possess antioxidant and antimicrobial properties in addition to being chemo- 
preventive and cytotoxic.
 
Against this backdrop, we designed and synthesized a new class 
of chalcones with dihydrobenzofuran moiety as A-ring and either substituted phenyl or 
pyrazole moiety as B-ring and evaluated their cytotoxic activity (fig 1). 
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Figure 1: Chemical sructures of new hybrid chalcones 1a-l and 2a-l
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The new class of hybrid chalcones was prepared through the ethanones 8 and 10. 
Synthesis of the ethanones 8 and 10 was started from resacetophenone 4
 
which could be 
Synopsis 
 
 
vi 
 
accessed easily from resorcinol (3) (Scheme 1). Mono-allylation of 4 with 3-chloro-2-
methylpropene gave the allyl-aryl ether 5 which on Claisen rearrangement afforded 6 in 
good yield. Acid catalyzed cyclization of the rearranged product 6 followed by the 
benzylation of the resulting benzofuran 7 afforded the ethanone 8 in very good yield. 
Compound 10, the regioisomer of 8, was prepared by benzylation of the 4-hydroxy group 
of 6 followed by acid catalyzed cyclization.  
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Scheme 1: Synthesis of ethanones 8 and 10
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The target 1,3-disubstituted-2-propen-1-ones (1a-l and 2a-l) were prepared by the 
Claisen-Schmidt condensation
 
of ethanone 8 or 10 withs various benzaldehydes (11a-f) 
and pyrazolaldehydes
 
(12a-f) in ethanolic NaOH (Scheme 2). The cytotoxic potential of 
all newly synthesized hybrid chalcones was evaluated in vitro against a panel of four 
tumor cell lines prostate cancer (PC-3), colon cancer (HT-29), lung cancer (NCI-H460) 
and mouse macrophages (B-16) using MTT assay
 
based on mitochondrial reduction of 
yellow MTT tetrazolium dye to a highly colored blue formazan product.
 
Doxorubicin was 
used as the reference drug.  
The new class of compounds showed significant to moderate cytotoxic activity on 
PC-3 cell lines (IC50 = 5.9-50 μM). Among the two regioisomeric core structures 8 and 
10, the derivatives of 10 showed more significant cytotoxic activity. It is also worthy to 
note that, the derivatives with pyrazole moiety as B-ring exhibited better activity over the 
Synopsis 
 
 
vii 
 
phenyl counterparts. Derivatives 2i, 2j and 2l exhibited significantly higher cytotoxicity 
with IC50 values 8.4, 7.9 and 5.9 μM respectively and most notably showed very low or 
no activity on the other three cell lines.  
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Scheme 2: Synthesis of hybrid chalcones  
In order to evaluate the effect of phenolic benzyl moiety, which initially was 
introduced as a protecting group to enable the synthesis, we prepared the O-debenzyl 
analogs of a few selected compounds with better activity and tested for their cytotoxic 
activity against PC-3 cell lines. The debenzylated compounds found to be less potent 
compared to the corresponding benzylated counterparts, presumably due to their 
decreased hydrophobicity. 
In conclusion, the present chapter described the synthesis and cytotoxic activity of 
a new class of hybrid-chalcones against four cell lines (PC-3, HT-29, B-16 and NCI-
H460). Most of the synthesized compounds are found to be selective towards PC-3 cell 
line. As the selectivity of the drug is an important parameter in cancer chemotherapy, the 
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newly synthesized compounds particularly 2i, 2j and 2l (IC50 = 8.4, 7.9 and 5.9 μM) 
could be potential anticancer drug candidates after further structure optimization. 
Chapter-IV: Synthesis and Biological Evaluation of New Rhodanine-3-acetamide 
Derivatives 
 This chapter deals with the introduction to biological importance of pyrazole 
amines with trifluoromethyl substitution, rhodanine-3-aceticetamide derivatives and 
describes the design, synthesis and biological (Cytotoxic & Larvicidal) evaluation of new 
pyrazolyl rhodanine acetamide derivatives. 
Synthesis and bioevaluation of rhodanine and rhodanine-3-acetic acid derivatives 
were studied extensively by many research groups. Very few reports on the synthesis and 
biological utility of rhodanine-3-acetamide derivatives are documented in the literature, 
in spite of their attractive biological profiles. Combination of two active pharmacophores 
within a single molecule is one of the strategies more often employed in the search for the 
lead molecule. The resulted new molecule would enhance the activity by an additive or 
synergistic effect. Inspired by this and the biological profiles of both 4-amino-3-trifluoro-
pyrazoles and rhodanine-3-acetic acid derivatives reported in the literature, we reasoned 
that incorporation of the structural characteristics of both these moieties to result a new 
rhodanine-3-acetamide derivatives with newer and/or better biological profiles. In the 
present study the design and synthesis of new rhodanine-3-acetamide derivatives and 
their biological evaluation have been carried out. 
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Synthesis of 1,5-diphenyl-3-(trifluoromethyl)-1H-pyrazol-4-amine (5) was started 
from 1,3-diketone (2) (Scheme 1), which in turn  was prepared from acetophenone (1) 
and ethyl trifluoromethyl acetate in presence of sodium methoxide in dry ether. 
Treatment of 1,3-diketone (2) with aqueous NaNO2 in acetic acid gave the diketo oxime 
(3) in good yield. Reaction of diketo oxime (3) with phenylhydrazine in dilute HCl 
afforded the nitroso-pyrazole (4) as a green solid. Reduction of the nitroso group by 
hydrogenation in presence of 10% Pd-C gave the aminopyrazole (5).  
Scheme 2: Synthesis of pyrazolyl rhodanine acetamide derivatives (9a-m)
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Treatment of the 4-aminopyrazole (5) with rhodanine-3-acetylchloride (6) gave 
the corresponding amide (7) in good yield. The acid chloride (6) was prepared from the 
corresponding rhodanine-3-acetic acid which in turn was prepared from glycine, carbon 
disulphide and sodium salt of chloroacetic acid using a reported procedure. Treatment of 
rhodanine-3-acetamide (7) with different aldehydes (8a-m) in presence of catalytic 
amount of piperidine in ethanol at room temperature gave the methylidine derivatives 
(9a-m) in good yields (Scheme 2).  
The cytotoxic potential of all the newly synthesized rhodanine-3-acetamide 
conjugates were evaluated in vitro against prostate (PC-3 & DU-145) and breast (MCF-7 
& MDA-MB-231) cancer cell lines using MTT assay
 
based on mitochondrial reduction of 
yellow MTT tetrazolium dye to a highly colored blue formazan product.
 
Doxorubicin was 
used as the reference drug. Most compounds, the heterocyclic conjugates in particular, 
displayed cytotoxicity against prostate cancer cell lines. The parent pyrazole amine 7 
exhibited appreciable activity against breast cancer cell lines. Compound 9e is potent 
against prostate cancer cell lines. The pyrazole conjugate 9k showed substantial 
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cytotoxicity towards all four cell lines. The derivatives 9e and 9k are the most promising 
with IC50 values 12.9 & 12.5 μM against PC-3 cell line.  
The larval toxicity study of all newly synthesized compounds was performed 
using standard protocol as described by World Health Organization (WHO, 1963), on 4
th
 
instar mosquito, C. quinquefasciatus larvae. The LC50 values of newly synthesized 
compounds (5, 7, 9a-m) were determined. Among these, only compound 9i showed 
toxicity against C. quinquefasciatus (LC50 = 8.42 ppm, 24 h). All other derivatives 
including 5 and 7 showed very low / no toxicity after 24 h and 48 h.  
In summary a new class of rhodanine-3-acetamide conjugates were synthesized 
and evaluated for their larvicidal and cytotoxic properties. Compound 9i showed toxicity 
against 4
th
 instar mosquito, C. quinquefasciatus larvae. The cytotoxic activity of these 
new derivatives were tested against prostate (PC-3 & DU-145) and breast (MCF-7 & 
MDA-MB-231) cancer cell lines. The derivatives 9e and 9k are the most promising 
compounds with IC50 values 12.9 & 12.5 μM against PC-3 cell lines.   
 
